News

Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.

2013

  • Dec 25, 2013 Chugai to Sign an Agreement to Enter China Medical City
    and to Establish an Import and Sales & Marketing Subsidiary
    “Chugai Pharma (China) Co., Ltd (Tentative Name).”
    [PDF 212KB]
  • Dec 24, 2013 Roche’s New Subcutaneous Formulation of RoACTEMRA
    Gains CHMP Positive Opinion in Europe
    for Moderate to Severe Rheumatoid Arthritis
    [PDF 270KB]
  • Nov 26, 2013 Personnel Changes
    [PDF 125KB]
  • Nov 22, 2013 Anti-Cancer Agent “Avastin®,”
    Obtained Approval for Additional Indication of Ovarian Cancer
    [PDF 289KB]
  • Nov 13, 2013 Anti-Cancer Agent, Antibody Drug Conjugate “Kadcyla®
    Postponement of Price Listing on the NHI Reimbursement List and
    Implementation of a New Clinical Study
    [PDF 182KB]
  • Nov 12, 2013 Helsinn and Chugai Pharma Marketing Enter into Agreement for Rights of
    Anamorelin, Currently in Development for Treatment of Anorexia-Cachexia
    Syndrome Related to Non-Small Cell Lung Cancer in Top EU Markets
    [PDF 53KB]
  • Oct 24, 2013 Supply Plan of "Tamiflu®" Anti-influenza Drug for the 2013-2014 Season
    [PDF 133KB]
  • Oct 23, 2013 Roche Gains FDA Approval for New Subcutaneous Formulation
    of ACTEMRA for Use in Adult Patients Living with
    Moderately to Severely Active Rheumatoid Arthritis
    [PDF 188KB]
  • Oct 17, 2013 F. Hoffmann-La Roche Announces Third Quarter Sales 2013
    [PDF 31KB]
  • Oct 11, 2013 Chugai Renews its “Story of Biotechnology” Website
    [PDF 279KB]
  • Oct 08, 2013 New Drug Application Filed for ALK Inhibitor “Alectinib Hydrochloride”
    for the Treatment of ALK Fusion Gene Positive
    Unresectable, Recurrent / Advanced Non-Small Cell Lung Cancer
    [PDF 182KB]
  • Sep 20, 2013 First HER2 targeted Antibody Drug Conjugate “Kadcyla®,”
    an Anti-Cancer Agent,
    Approved for HER2-positive Inoperable or Recurrent Breast Cancer
    [PDF 182KB]
  • Sep 17, 2013 Contribution of Para-transit Vehicles to Welfare Services
    [PDF 222KB]
  • Sep 12, 2013 Launch of the Anti-Cancer Agent “Perjeta®
    [PDF 300KB]
  • Sep 11, 2013 Chugai to Give a Course on the “Pharmaceutical Industry”
    at Faculty of Economics, The University of Tokyo
    [PDF 240KB]
  • Sep 06, 2013 Organizational and Personnel Changes
    [PDF 195KB]
  • Sep 02, 2013 Chugai to Support Japan Paralympic Committee as an Official Partner
    [PDF 206KB]
  • Aug 29, 2013 Launch of the New Agent for Osteoporosis
    “Bonviva® Injection 1 mg Syringe”
    [PDF 142KB]
  • Aug 23, 2013 Roche Diagnostics and Chugai Pharmaceutical Present
    a Biology Science Laboratory Targeting High School Students
    [PDF 216KB]
  • Aug 22, 2013 Drug Application Filed for Additional Form of Immunosuppressant,
    “CellCept® Powder for Oral Suspension 32%”
    [PDF 124KB]
  • Jul 25, 2013 Organizational and Personnel Changes
    [PDF 165KB]
  • Jul 25, 2013 F. Hoffmann-La Roche Announces Second Quarter Sales 2013
    [PDF 16KB]
  • Jul 01, 2013 Extension of the Shelf-Life for the Anti-Influenza Virus Drug
    Tamiflu®Capsules 75
    [PDF 290KB]
  • Jun 28, 2013 New Agent for Osteoporosis Approved in Japan
    “Bonviva® IV Injection”
    [PDF 18KB]
  • Jun 28, 2013 Anti-Cancer Agent “Perjeta®
    Approved for HER2-positive Inoperable or Recurrent Breast Cancer
    [PDF 230KB]
  • Jun 14, 2013 Anti-Cancer Agent “Avastin®,"
    Obtained Approval for Additional Indication and
    Dosage and Administration of Malignant Glioma
    [PDF 186KB]
  • Jun 14, 2013 Anti-Cancer Agent “Tarceva®,”
    Obtained Approval for Additional Indication (First Line Therapy) of
    Non-Small Cell Lung Cancer with EGFR Mutations
    [PDF 218KB]
  • Jun 14, 2013 Anti-Cancer Agent, Herceptin®
    Obtained Approval for Dosage and Administration for
    Postoperative Adjuvant Chemotherapy in Breast Cancer
    [PDF 177KB]
  • Jun 13, 2013 Roche’s RoACTEMRA Shows Long-Term Efficacy
    in Monotherapy and also Benefits in Early Rheumatoid Arthritis
    [PDF 251KB]
  • Jun 10, 2013 Roche’s RoACTEMRA Approved in EU
    to Treat Children with Rare Form of Arthritis
    [PDF 263KB]
  • May 24, 2013 Launch of Subcutaneous Injection Formulation, Actemra®,
    for a Treatment of Rheumatoid Arthritis
    The First Anti-IL-6 Receptor Antibody in Subcutaneous Market
    [PDF 384KB]
  • May 13, 2013 Determination of Terms and Conditions of Stock Options
    (Stock Acquisition Rights)
    [PDF 50KB]
  • May 07, 2013 Results of a Phase I/II Clinical Trial of a New Anti-Malignant Agent,
    AF802, for ALK-Positive Non-Small Cell Lung Cancer
    were Published Online on “The Lancet Oncology”
    [PDF 189KB]
  • May 07, 2013 FDA Approves ACTEMRA® for Children
    Living with a Rare Form of Arthritis
    [PDF 181KB]
  • Apr 25, 2013 Issuance of Stock Options (Stock Acquisition Rights)
    [PDF 78KB]
  • Apr 19, 2013 Results of Phase II/III Clinical Trial of Ibandronate Sodium Hydrate
    Injection, Bisphosphonate Antiresorptive Agent,
    in Japanese Patients with Osteoporosis Presented
    [PDF 22KB]
  • Apr 11, 2013 F. Hoffmann-La Roche Announces First Quarter Sales 2013
    [PDF 27KB]
  • Apr 08, 2013 Dainippon Sumitomo Pharma and Chugai Pharmaceutical
    Terminate Joint Development of Cancer Vaccine
    [PDF 32KB]
  • Apr 05, 2013 Personnel Changes
    [PDF 124KB]
  • Mar 25, 2013 Actemra®, a Treatment for Rheumatoid Arthritis
    Obtained Approval for Subcutaneous Injection Formulation
    [PDF 55KB]
  • Mar 14, 2013 Chugai to Receive a Letter of Appreciation from
    the Minister of Health, Labour and Welfare for Our Activities to
    Support the Victims of the Great East Japan Earthquake
    [PDF 301KB]
  • Mar 01, 2013 The Peking University Chugai Medical Foundation Established
    by Chugai’s Donations to Support Peking University’s Medical Students
    [PDF 246KB]
  • Feb 26, 2013 FDA Accepts Biologics License Application Submitted for Subcutaneous
    Formulation of ACTEMRA®, a Treatment for Rheumatoid Arthritis
    [PDF 181KB]
  • Feb 19, 2013 Filing of Lawsuit on Patent Infringement Concerning Oxarol® Ointment, and
    a Petition for Provisional Disposition Order
    [PDF 67KB]
  • Feb 07, 2013 Anti-Cancer Agent, Herceptin®, Filed for Additional Dosage and Administration
    for Postoperative Adjuvant Chemotherapy in Breast Cancer
    By “New Drug Application Based on Evidence in the Public Domain”
    [PDF 168KB]
  • Jan 30, 2013 Personnel Changes
    [PDF 176KB]
  • Jan 30, 2013 F. Hoffmann-La Roche Announces Financial Results for Fiscal 2012
    [PDF 45KB]
  • Jan 29, 2013 New Drug Application Filed for Antibody-Drug Conjugate
    Trastuzumab Emtansine for the Treatment of
    HER2-Positive Metastatic or Recurrent Breast Cancer
    [PDF 178KB]
  • Jan 08, 2013 Chugai and Debiopharm GroupTMAnnounce an Exclusive License
    Agreement for Anti-Cancer Agent, FF284 (Debio 1347)
    [PDF 38KB]
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top